Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "EMA"

2996 News Found

BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy
Clinical Trials | December 11, 2025

BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first


Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
Drug Approval | December 11, 2025

Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients

The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies


Bristol Myers Squibb unveils breakthrough Lymphoma data
News | December 11, 2025

Bristol Myers Squibb unveils breakthrough Lymphoma data

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas


Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids
Biopharma | December 10, 2025

Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids

The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities


Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion
Biotech | December 10, 2025

Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion

This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing


Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
News | December 10, 2025

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors


Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
News | December 09, 2025

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones


Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug
News | December 09, 2025

Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma


Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial
Clinical Trials | December 09, 2025

Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial

It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)